公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2011 | Biomarker Analysis in Bo21015, a Phase Ii Randomised Study of First-Line Bevacizumab (Bev) Combined with Carboplatin-Gemcitabine (Cg) or Carboplatin-Paclitaxel (Cp) in Patients (Pts) with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer (Nscl | YU, CHONG-JEN | EUROPEAN JOURNAL OF CANCER |